Zenas BioPharma, Inc. (ZBIO)
(Delayed Data from NSDQ)
$30.19 USD
-1.61 (-5.06%)
Updated Oct 28, 2025 03:59 PM ET
After-Market: $30.30 +0.11 (0.36%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZBIO 30.19 -1.61(-5.06%)
Will ZBIO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ZBIO based on the 1-3 month trading system that more than doubles the S&P 500.

Other News for ZBIO
ZBIO: Citigroup Raises Price Target, Maintains Buy Rating | ZBIO Stock News
ZBIO: Morgan Stanley Raises Price Target, Maintains Overweight Rating | ZBIO Stock News
ZBIO: HC Wainwright & Co. Raises Price Target, Maintains 'Buy' Rating | ZBIO Stock News
Crossed Above 20 Day Moving Average appears for ZBIO after 33.08% move
Zenas BioPharma price target raised to $34 from $31 at Morgan Stanley